| Name | Title | Contact Details |
|---|
MethylGene Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Fate Therapeutics is interrogating stem cell biology to develop therapeutics based on modulating cell fate and to enable a new drug discovery paradigm with the Companys proprietary induced-pluripotent stem (iPS) cell technology.
Caliper Life Sciences is a Hopkinton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AgBiome is a biotechnology company using new knowledge of the plant-associated microbiome to create innovative products for agriculture. We have compiled the world`s largest collection of fully-sequenced and annotated microbes from the crop microbiome, and we are screening this collection with validated, proprietary pipelines to discover new biologicals and trait genes. Partnerships with leading agricultural companies such as Syngenta and Genective accelerate our discovery process and allow us to deliver solutions to global markets. We employ 36 full-time and 14 part-time employees and will occupy a new state-of-the-art 30,000 square foot laboratory and greenhouse facility in early 2016. AgBiome`s products will help farmers combat many of the most important unsolved problems in agriculture, including insects, nematodes, and diseases. Our first product, a biological fungicide, has been submitted for regulatory review, with first sales anticipated in 2016.
Regulus is focused on the discovery and development of microRNA therapeutics. microRNAs are members of a large class of non-coding RNAs of approximately 22 nucleotides in length that regulate most genes in the genome. A single microRNA can target and regulate up to hundreds of genes, and these genes are involved in biological networks or pathways. Dysregulated microRNA expression is involved in the initiation of many complex multi-factoral diseases, including cancer, inflammatory disease, fibrosis, and metabolic disease. microRNA therapeutics are oligonucleotide medicines that modulate the function of microRNAs, correcting the imbalance of gene expression and associated cellular pathways to treat human disease. Regulus was formed in September 2007 by Alnylam Pharmaceuticals (NASDAQ:ALNY) and Isis Pharmaceuticals (NASDAQ:ISIS). Regulus benefits substantially from the collective therapeutic RNA expertise of its founding companies, including established proprietary oligonucleotide-based technologies, and broad and dominant intellectual property estates specific to chemically modified oligonucleotides. Regulus has access to over 900 patents and patent applications pertaining to oligonucleotide technologies useful for targeting microRNA therapeutics, and over 170 patents and patent applications directed to microRNA specific technologies. Regulus is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and drug development. Regulus’ scientific advisory board consists of world-class scientists and several of the foremost authorities in the field of microRNA research.